The pleiotropic benefits of statins include the ability to reduce CD47 and amplify the effect of pro-efferocytic therapies in atherosclerosis


Journal article


K. Jarr, J. Ye, Y. Kojima, Z. Ye, H. Gao, S. Schmid, L. Luo, R. Baylis, M. Lotfi, N. Lopez, A. Eberhard, B. Smith, I. Weissman, L. Maegdefessel, N. Leeper
Nature Cardiovascular Research, 2022

Semantic Scholar DOI PubMedCentral PubMed
Cite

Cite

APA   Click to copy
Jarr, K., Ye, J., Kojima, Y., Ye, Z., Gao, H., Schmid, S., … Leeper, N. (2022). The pleiotropic benefits of statins include the ability to reduce CD47 and amplify the effect of pro-efferocytic therapies in atherosclerosis. Nature Cardiovascular Research.


Chicago/Turabian   Click to copy
Jarr, K., J. Ye, Y. Kojima, Z. Ye, H. Gao, S. Schmid, L. Luo, et al. “The Pleiotropic Benefits of Statins Include the Ability to Reduce CD47 and Amplify the Effect of pro-Efferocytic Therapies in Atherosclerosis.” Nature Cardiovascular Research (2022).


MLA   Click to copy
Jarr, K., et al. “The Pleiotropic Benefits of Statins Include the Ability to Reduce CD47 and Amplify the Effect of pro-Efferocytic Therapies in Atherosclerosis.” Nature Cardiovascular Research, 2022.


BibTeX   Click to copy

@article{k2022a,
  title = {The pleiotropic benefits of statins include the ability to reduce CD47 and amplify the effect of pro-efferocytic therapies in atherosclerosis},
  year = {2022},
  journal = {Nature Cardiovascular Research},
  author = {Jarr, K. and Ye, J. and Kojima, Y. and Ye, Z. and Gao, H. and Schmid, S. and Luo, L. and Baylis, R. and Lotfi, M. and Lopez, N. and Eberhard, A. and Smith, B. and Weissman, I. and Maegdefessel, L. and Leeper, N.}
}

Computational Modeling Predicts Benefits of Proefferocytic Therapy in Human Atherosclerosis


K. Jarr, K. Palm, G. Pasterkamp, M. Mokry, N. Leeper

Circulation, 2025


Smooth muscle cells in atherosclerosis: essential but overlooked translational perspectives


P. Azar, K. Jarr, D. Gomez, H. Jorgensen, N. Leeper, M. Bochaton-Piallat

European Heart Journal, 2025


The pleiotropic benefits of statins include the ability to reduce CD47 and amplify the effect of pro-efferocytic therapies in atherosclerosis


K. Jarr, J. Ye, Y. Kojima, Z. Ye, H. Gao, S. Schmid, L. Luo, R. Baylis, M. Lotfi, N. Lopez, A. Eberhard, B. Smith, I. Weissman, L. Maegdefessel, N. Leeper

Nature Cardiovascular Research, 2022


Effect of CD47 Blockade on Vascular Inflammation.


K. Jarr, R. Nakamoto, B. Doan, Y. Kojima, I. Weissman, R. Advani, A. Iagaru, N. Leeper

New England Journal of Medicine, 2021


Chitinase 3 like 1 (CHI3L1) is a regulator of smooth muscle cell physiology and atherosclerotic lesion stability


P. Tsantilas, S. Lao, Z. Wu, A. Eberhard, G. Winski, M. Vaerst, V. Nanda, Y. Wang, Y. Kojima, J. Ye, A. Flores, K. Jarr, J. Pelisek, H. Eckstein, L. Matic, U. Hedin, P. Tsao, V. Paloschi, L. Maegdefessel, N. Leeper

Cardiovascular Research, 2021


Pro-efferocytic nanoparticles are specifically taken up by lesional macrophages and prevent atherosclerosis


A. Flores, N. Hosseini-Nassab, K. Jarr, J. Ye, X. Zhu, R. Wirka, A. Koh, P. Tsantilas, Y. Wang, V. Nanda, Y. Kojima, Y. Zeng, M. Lotfi, R. Sinclair, I. Weissman, E. Ingelsson, B. Smith, N. Leeper

Nature Nanotechnology, 2020


18F-Fluorodeoxyglucose-Positron Emission Tomography Imaging Detects Response to Therapeutic Intervention and Plaque Vulnerability in a Murine Model of Advanced Atherosclerotic Disease


K. Jarr, Jianqin Ye, Y. Kojima, V. Nanda, Alyssa M. Flores, P. Tsantilas, Ying Wang, Niloufar Hosseini-Nassab, Anne V. Eberhard, Mozhgan Lotfi, Max Käller, B. Smith, L. Maegdefessel, N. Leeper

Arteriosclerosis, Thrombosis and Vascular Biology, 2020


Knockout of the Murine Ortholog to the Human 9p21 Coronary Artery Disease Locus Leads to Smooth Muscle Cell Proliferation, Vascular Calcification, and Advanced Atherosclerosis


Y. Kojima, J. Ye, V. Nanda, Y. Wang, A. Flores, K. Jarr, P. Tsantilas, L. Guo, A. Finn, R. Virmani, N. Leeper

Circulation, 2020


Clonally expanding smooth muscle cells promote atherosclerosis by escaping efferocytosis and activating the complement cascade


Y. Wang, V. Nanda, D. Direnzo, J. Ye, S. Xiao, Y. Kojima, K. Howe, K. Jarr, A. Flores, P. Tsantilas, N. Tsao, A. Rao, A. Newman, A. Eberhard, J. Priest, A. Ruusalepp, G. Pasterkamp, L. Maegdefessel, C. Miller, L. Lind, S. Koplev, J. Björkegren, G. Owens, E. Ingelsson, I. Weissman, N. Leeper

Proceedings of the National Academy of Sciences of the United States of America, 2020


Nanoparticle Therapy for Vascular Diseases


A. Flores, J. Ye, K. Jarr, N. Hosseini-Nassab, B. Smith, N. Leeper

Arteriosclerosis, Thrombosis and Vascular Biology, 2019


Initial Single-Center Experience With the Fully Repositionable Transfemoral Lotus Aortic Valve System


K. Jarr, F. Leuschner, B. Meder, H. Katus, R. Bekeredjian, E. Chorianopoulos

The Journal of Invasive Cardiology, 2016


Heat-shock-protein 90 protects from downregulation of HIF-1α in calcineurin-induced myocardial hypertrophy


S. Eschricht, K. Jarr, C. Kuhn, Lorenz L. Lehmann, M. Kreusser, H. Katus, N. Frey, E. Chorianopoulos

Journal of Molecular and Cellular Cardiology, 2015


TNF-Like Weak Inducer of Apoptosis Aggravates Left Ventricular Dysfunction after Myocardial Infarction in Mice


K. Jarr, S. Eschricht, L. Burkly, M. Preusch, H. Katus, N. Frey, E. Chorianopoulos

Mediators of Inflammation, 2014


MicroRNA-20a inhibits stress-induced cardiomyocyte apoptosis involving its novel target Egln3/PHD3


D. Frank, J. Gantenberg, I. Boomgaarden, C. Kuhn, Rainer Will, K. Jarr, M. Eden, Kristina Kramer, M. Luedde, H. Mairbäurl, H. Katus, N. Frey

Journal of Molecular and Cellular Cardiology, 2012


Soluble TWEAK is markedly upregulated in patients with ST-elevation myocardial infarction and related to an adverse short-term outcome


E. Chorianopoulos, K. Jarr, H. Steen, E. Giannitsis, N. Frey, H. Katus

Atherosclerosis, 2010